Preventing
With sparsentan (Filspari) now the second IgAN agent to earn full approval for reducing kidney function loss, Jonathan Barratt, PhD, FRCP, reflects on the significance of recent advancements in IgAN and looks ahead to what the future may hold for the field of #nephrology.
https://www.hcplive.com/view/jonathan...